AAAAAA

   
Results: 1-25 | 26-33
Results: 1-25/33
A PHASE-II WINDOW STUDY OF TOPOTECAN IN UNTREATED PATIENTS WITH HIGH-RISK ADULT ACUTE LYMPHOBLASTIC-LEUKEMIA
Authors: GORE SD ROWINSKY EK MILLER CB GRIFFIN C CHEN TL BOROWITZ M DONEHOWER RC BURKS KL ARMSTRONG DK BURKE PJ GREVER MR KAUFMANN SH
Citation: Sd. Gore et al., A PHASE-II WINDOW STUDY OF TOPOTECAN IN UNTREATED PATIENTS WITH HIGH-RISK ADULT ACUTE LYMPHOBLASTIC-LEUKEMIA, Clinical cancer research, 4(11), 1998, pp. 2677-2689
TOPOISOMERASE-II AND THE RESPONSE TO ANTILEUKEMIC THERAPY
Authors: KAUFMANN SH GORE SD MILLER CB JONES RJ ZWELLING LA SCHNEIDER E BURKE PJ KARP JE
Citation: Sh. Kaufmann et al., TOPOISOMERASE-II AND THE RESPONSE TO ANTILEUKEMIC THERAPY, Leukemia & lymphoma, 29(3-4), 1998, pp. 217-237
IMPACT OF EXOGENOUS GROWTH-FACTORS ON PROLIFERATION AND CHEMOSENSITIVITY OF MINIMAL RESIDUAL ACUTE MYELOID-LEUKEMIA
Authors: GORE SD BURKE PJ WENG LJ
Citation: Sd. Gore et al., IMPACT OF EXOGENOUS GROWTH-FACTORS ON PROLIFERATION AND CHEMOSENSITIVITY OF MINIMAL RESIDUAL ACUTE MYELOID-LEUKEMIA, Leukemia & lymphoma, 29(3-4), 1998, pp. 339-350
INHIBITED APOPTOSIS AND DRUG-RESISTANCE IN ACUTE MYELOID-LEUKEMIA
Authors: SMITH BD BAMBACH BJ VALA MS BARBER JP ENGER C BRODSKY RA BURKE PJ GORE SD JONES RJ
Citation: Bd. Smith et al., INHIBITED APOPTOSIS AND DRUG-RESISTANCE IN ACUTE MYELOID-LEUKEMIA, British Journal of Haematology, 102(4), 1998, pp. 1042-1049
ELEVATED EXPRESSION OF THE APOPTOTIC REGULATOR MCL-1 AT THE TIME OF LEUKEMIC RELAPSE
Authors: KAUFMANN SH KARP JE SVINGEN PA KRAJEWSKI S BURKE PJ GORE SD REED JC
Citation: Sh. Kaufmann et al., ELEVATED EXPRESSION OF THE APOPTOTIC REGULATOR MCL-1 AT THE TIME OF LEUKEMIC RELAPSE, Blood, 91(3), 1998, pp. 991-1000
IMPACT OF THE PUTATIVE DIFFERENTIATING AGENTS SODIUM PHENYLBUTYRATE AND SODIUM PHENYLACETATE ON PROLIFERATION, DIFFERENTIATION, AND APOPTOSIS OF PRIMARY NEOPLASTIC MYELOID CELLS
Authors: GORE SD SAMID D WENG LJ
Citation: Sd. Gore et al., IMPACT OF THE PUTATIVE DIFFERENTIATING AGENTS SODIUM PHENYLBUTYRATE AND SODIUM PHENYLACETATE ON PROLIFERATION, DIFFERENTIATION, AND APOPTOSIS OF PRIMARY NEOPLASTIC MYELOID CELLS, Clinical cancer research, 3(10), 1997, pp. 1755-1762
ADDITION OF ETOPOSIDE TO INITIAL THERAPY OF ADULT ACUTE LYMPHOBLASTIC-LEUKEMIA - A COMBINED CLINICAL AND LABORATORY STUDY (VOL 23, PG 71, PG 1996)
Authors: KAUFMANN SH KARP JE BURKE PJ GORE SD
Citation: Sh. Kaufmann et al., ADDITION OF ETOPOSIDE TO INITIAL THERAPY OF ADULT ACUTE LYMPHOBLASTIC-LEUKEMIA - A COMBINED CLINICAL AND LABORATORY STUDY (VOL 23, PG 71, PG 1996), Leukemia & lymphoma, 24(5-6), 1997, pp. 3-3
SYNERGY BETWEEN RETINOIC ACID (IU) AND THE PUTATIVE DIFFERENTIATING AGENT SODIUM PHENYLBUTYRATE (SPB) PROMOTES MAXIMAL CYTOSTASIS AND DIFFERENTIATION OF MYELOID CELLS AT CLINICALLY ACHIEVABLE DOSES OF SPB
Authors: WENG LJ YU K FU S GORE SD
Citation: Lj. Weng et al., SYNERGY BETWEEN RETINOIC ACID (IU) AND THE PUTATIVE DIFFERENTIATING AGENT SODIUM PHENYLBUTYRATE (SPB) PROMOTES MAXIMAL CYTOSTASIS AND DIFFERENTIATION OF MYELOID CELLS AT CLINICALLY ACHIEVABLE DOSES OF SPB, Blood, 90(10), 1997, pp. 1469-1469
LONG-TERM FOLLOW-UP OF INTENSIVE, ARA-C-BASED CHEMOTHERAPY FOLLOWED BY BONE-MARROW TRANSPLANTATION (BMT) FOR ADULT ACUTE LYMPHOCYTIC-LEUKEMIA (ALL) - IMPROVED SURVIVAL WITH ALLOGENEIC, BUT NOT AUTOLOGOUS BMT
Authors: SOTOMAYOR EM PIANTADOSI S MILLER CB KARP JE KAUFMANN SH BRAINE H HUMPHREY RL BURKE PJ GORE SD
Citation: Em. Sotomayor et al., LONG-TERM FOLLOW-UP OF INTENSIVE, ARA-C-BASED CHEMOTHERAPY FOLLOWED BY BONE-MARROW TRANSPLANTATION (BMT) FOR ADULT ACUTE LYMPHOCYTIC-LEUKEMIA (ALL) - IMPROVED SURVIVAL WITH ALLOGENEIC, BUT NOT AUTOLOGOUS BMT, Blood, 90(10), 1997, pp. 1484-1484
INHIBITED APOPTOSIS AND DRUG-RESISTANCE IN ACUTE MYELOID-LEUKEMIA (AML)
Authors: SMITH BD BAMBACH BJ VALA MS BARBER JP ENGER C BRODSKY RA BURKE PJ GORE SD JONES RJ
Citation: Bd. Smith et al., INHIBITED APOPTOSIS AND DRUG-RESISTANCE IN ACUTE MYELOID-LEUKEMIA (AML), Blood, 90(10), 1997, pp. 1732-1732
ALTERED FORMATION OF TOPOTECAN-STABILIZED TOPOISOMERASE-I DNA-ADDUCTSIN HUMAN LEUKEMIA-CELLS
Authors: KAUFMANN SH SVINGEN PA GORE SD ARMSTRONG DK CHENG YC ROWINSKY EK
Citation: Sh. Kaufmann et al., ALTERED FORMATION OF TOPOTECAN-STABILIZED TOPOISOMERASE-I DNA-ADDUCTSIN HUMAN LEUKEMIA-CELLS, Blood, 89(6), 1997, pp. 2098-2104
IDENTIFICATION OF THE LARGEST INDIVIDUAL-SAMPLE VALUE USING COMPOSITESAMPLE DATA AND CERTAIN MODIFICATIONS OF THE SWEEP-OUT METHOD
Authors: GORE SD PATIL GP TAILLIE C
Citation: Sd. Gore et al., IDENTIFICATION OF THE LARGEST INDIVIDUAL-SAMPLE VALUE USING COMPOSITESAMPLE DATA AND CERTAIN MODIFICATIONS OF THE SWEEP-OUT METHOD, Environmental and ecological statistics, 3(3), 1996, pp. 219-234
ANNOTATED-BIBLIOGRAPHY OF COMPOSITE SAMPLING PART-A - 1936-92
Authors: BOSWELL MT GORE SD LOVISON G PATIL GP
Citation: Mt. Boswell et al., ANNOTATED-BIBLIOGRAPHY OF COMPOSITE SAMPLING PART-A - 1936-92, Environmental and ecological statistics, 3(1), 1996, pp. 1-50
A PHASE-I AND PHARMACOLOGICAL STUDY OF TOPOTECAN INFUSED OVER 30 MINUTES FOR 5 DAYS IN PATIENTS WITH REFRACTORY ACUTE-LEUKEMIA
Authors: ROWINSKY EK KAUFMANN SH BAKER SD MILLER CB SARTORIUS SE BOWLING MK CHEN TL DONEHOWER RC GORE SD
Citation: Ek. Rowinsky et al., A PHASE-I AND PHARMACOLOGICAL STUDY OF TOPOTECAN INFUSED OVER 30 MINUTES FOR 5 DAYS IN PATIENTS WITH REFRACTORY ACUTE-LEUKEMIA, Clinical cancer research, 2(12), 1996, pp. 1921-1930
ADDITION OF ETOPOSIDE TO INITIAL THERAPY OF ADULT ACUTE LYMPHOBLASTIC-LEUKEMIA - A COMBINED CLINICAL AND LABORATORY STUDY
Authors: KAUFMANN SH KARP JE BURKE PJ GORE SD
Citation: Sh. Kaufmann et al., ADDITION OF ETOPOSIDE TO INITIAL THERAPY OF ADULT ACUTE LYMPHOBLASTIC-LEUKEMIA - A COMBINED CLINICAL AND LABORATORY STUDY, Leukemia & lymphoma, 23(1-2), 1996, pp. 71-83
GROWTH-FACTOR MODULATION OF P21(WAF1 CIP1) IN PRIMARY ACUTE MYELOID LEUKEMIAS/
Authors: DIGIUSEPPE JA GORE SD WENG LJ KASTAN MB
Citation: Ja. Digiuseppe et al., GROWTH-FACTOR MODULATION OF P21(WAF1 CIP1) IN PRIMARY ACUTE MYELOID LEUKEMIAS/, Blood, 88(10), 1996, pp. 331-331
IMPROVED HEMATOPOIESIS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE MYELOID-LEUKEMIA (AML) FOLLOWING ADMINISTRATION OF THE PUTATIVE DIFFERENTIATING AGENT SODIUM PHENYLBURYRATE (SPB)
Authors: GORE SD MILLER CB WENG LJ BURKS K GRIFFIN CA CHEN TL BURKE PJ GREVER M ROWINSKY EK
Citation: Sd. Gore et al., IMPROVED HEMATOPOIESIS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE MYELOID-LEUKEMIA (AML) FOLLOWING ADMINISTRATION OF THE PUTATIVE DIFFERENTIATING AGENT SODIUM PHENYLBURYRATE (SPB), Blood, 88(10), 1996, pp. 2315-2315
IMPACT OF IN-VIVO ADMINISTRATION OF INTERLEUKIN-3 ON PROLIFERATION, DIFFERENTIATION, AND CHEMOSENSITIVITY OF ACUTE MYELOID-LEUKEMIA
Authors: GORE SD WENG LJ JONES RJ COWAN K ZILCHA M PIANTADOSI S BURKE PJ
Citation: Sd. Gore et al., IMPACT OF IN-VIVO ADMINISTRATION OF INTERLEUKIN-3 ON PROLIFERATION, DIFFERENTIATION, AND CHEMOSENSITIVITY OF ACUTE MYELOID-LEUKEMIA, Clinical cancer research, 1(3), 1995, pp. 295-303
STEEL FACTOR SUPPORTS THE CYCLING OF ISOLATED HUMAN CD34(-FACTORS() CELLS IN THE ABSENCE OF OTHER GROWTH)
Authors: GORE SD AMIN S WENG LJ CIVIN CI
Citation: Sd. Gore et al., STEEL FACTOR SUPPORTS THE CYCLING OF ISOLATED HUMAN CD34(-FACTORS() CELLS IN THE ABSENCE OF OTHER GROWTH), Experimental hematology, 23(5), 1995, pp. 413-421
LONG-TERM SURVIVAL OF SUBSETS OF PATIENTS WITH ADVANCED MYELODYSPLASTIC SYNDROMES (MDS) TREATED WITH INTENSIVE CHEMOTHERAPY
Authors: GORE SD BURKE PJ
Citation: Sd. Gore et Pj. Burke, LONG-TERM SURVIVAL OF SUBSETS OF PATIENTS WITH ADVANCED MYELODYSPLASTIC SYNDROMES (MDS) TREATED WITH INTENSIVE CHEMOTHERAPY, Blood, 86(10), 1995, pp. 1342-1342
THE PROGNOSTIC FACTOR SCORE MODEL AND A SEQUENTIAL LIKELIHOOD RATIO TEST RAPIDLY DETERMINE THE VALUE OF TRANSLATIONAL INTERVENTION IN PATIENTS WITH MINIMAL RESIDUAL AML
Authors: BURKE PJ ZAHURAK M GORE SD ADJEI A STRYZAK J
Citation: Pj. Burke et al., THE PROGNOSTIC FACTOR SCORE MODEL AND A SEQUENTIAL LIKELIHOOD RATIO TEST RAPIDLY DETERMINE THE VALUE OF TRANSLATIONAL INTERVENTION IN PATIENTS WITH MINIMAL RESIDUAL AML, Blood, 86(10), 1995, pp. 2995-2995
GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (CM-CSF), GIVEN CONCURRENTLY WITH INDUCTION THERAPY FOR ACUTE MYELOGENOUS LEUKEMIA (AML), AUGMENTS THE SYNDROME OF T-LYMPHOCYTE RECOVERY
Authors: GORE SD DONNENBERG AD ZEHNBAUER BA WENG LJ BURKE PJ
Citation: Sd. Gore et al., GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (CM-CSF), GIVEN CONCURRENTLY WITH INDUCTION THERAPY FOR ACUTE MYELOGENOUS LEUKEMIA (AML), AUGMENTS THE SYNDROME OF T-LYMPHOCYTE RECOVERY, Leukemia, 8(3), 1994, pp. 409-419
IDENTIFICATION OF GROWTH FACTOR-RESPONSIVE ACUTE MYELOGENOUS LEUKEMIABASED ON FACTOR-DEPENDENCE FOR SURVIVAL AND PROLIFERATION
Authors: GORE SD WENG LJ BURKE PJ
Citation: Sd. Gore et al., IDENTIFICATION OF GROWTH FACTOR-RESPONSIVE ACUTE MYELOGENOUS LEUKEMIABASED ON FACTOR-DEPENDENCE FOR SURVIVAL AND PROLIFERATION, Leukemia, 8(11), 1994, pp. 1854-1863
PHASE-I AND PHARMACODYNAMIC STUDY OF THE TOPOISOMERASE I-INHIBITOR TOPOTECAN IN PATIENTS WITH REFRACTORY ACUTE-LEUKEMIA
Authors: ROWINSKY EK ADJEI A DONEHOWER RC GORE SD JONES RJ BURKE PJ CHENG YC GROCHOW LB KAUFMANN SH
Citation: Ek. Rowinsky et al., PHASE-I AND PHARMACODYNAMIC STUDY OF THE TOPOISOMERASE I-INHIBITOR TOPOTECAN IN PATIENTS WITH REFRACTORY ACUTE-LEUKEMIA, Journal of clinical oncology, 12(10), 1994, pp. 2193-2203
WILL GROWTH-FACTOR AUGMENTATION DURING POSTREMISSION THERAPY FOR AML OVERCOME DRUG-RESISTANCE
Authors: WENG LJ BURKE PJ GORE SD
Citation: Lj. Weng et al., WILL GROWTH-FACTOR AUGMENTATION DURING POSTREMISSION THERAPY FOR AML OVERCOME DRUG-RESISTANCE, Experimental hematology, 22(8), 1994, pp. 772-772
Risultati: 1-25 | 26-33